Mangalam Drugs and Organics Limited

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
91-22-62616200 / 6300 / 8787 91-22-62619090 • CIN : L24230MH1972PLC116413

MANGALAM
WHO-GMP
Accredited

REF: MDOL/CS-SE/2026-27/045

November 18th, 2026

To,
Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 532637

Listing Department
National Stock Exchange of India Limited
"Exchange Plaza", 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051

Symbol: MANGALAM

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 –Proposal for Sale of Company's undertaking.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III thereto, and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (Chapter V, Section V-A, read with Annexure 18 and Annexure 18A thereto), we wish to inform you that the Board of Directors of the Company, at its meeting held on Wednesday, 18th November, 2026, considered and approved the proposal for undertaking financial restructuring and exploring various strategic options for the Company, including the potential sale/disposal of the Company's leasehold land rights and building situated at Unit-2, Plot No. 1203, GIDC, Vapi, District Valsad, Gujarat – 396195.

In this regard, the Board has also approved convening the Extra-Ordinary General Meeting (EGM) of the Members of the Company for the financial year 2026-27 to seek their approval, wherever required under applicable laws, in respect of the proposed strategic options and to authorise the Board of Directors to take all necessary steps and actions in this regard.

It is clarified that the proposal is presently at an exploratory stage and the Company has not entered into any definitive agreement or arrangement for the proposed sale/disposal. The identity of the prospective buyer(s), consideration, commercial terms and other transaction-related particulars shall be determined at an appropriate stage, subject to necessary approvals and compliance with applicable laws.

The relevant disclosures in respect of the proposed sale/disposal of the aforesaid undertaking, in accordance with Regulation 30 of the SEBI Listing Regulations, are enclosed herewith as **Annexure-1**.

Mangalam Drugs and Organics Limited

Regd: Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
91-22-62616200 / 6300 / 8787 91-22-62619090 • CIN : L24230MH1972PLC116413

MANGALAM
WHO-GMP
Accredited

The aforesaid information shall also be made available on the Company's website at www.mangalamdrugs.com.

The Meeting of the board of Directors of the Company commenced at 02:30 p.m. and concluded at 05:00 p.m.

Kindly take the same on record. Thanking you,
***For* Mangalam Drugs and Organics Limited**

GOVARDHAN MURLIDHAR DHOOT
Digitally signed by GOVARDHAN MURLIDHAR DHOOT
Date: 2026.11.18 18:45:09 +05'30'

Govardhan Murlidhar Dhoot
Managing Director
DIN: 01240086

Mangalam Drugs and Organics Limited

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
☎ 91-22-62616200 / 6300 / 8787 📠 91-22-62619090 • CIN : L24230MH1972PLC116413

MANGALAM
WHO-GMP
Accredited

ANNEXURE-1

CONTINUOUS DISCLOSURE UNDER SUB-PARA 1 OF PARA A OF PART A OF SCHEDULE III PURSUANT TO REGULATION 30 OF THE SEBI (LODR) REGULATION, 2015

Particulars of the proposed sale/disposal of leasehold land rights and building situated at Unit-2, Plot No. 1203, GIDC, Vapi, District Valsad, Gujarat – 396195

<table>
<tr><th>Sr. No.</th><th>Particulars</th><th>Details</th></tr>
<tr><td>1</td><td>The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;</td><td>
<table>
<tr><th>Sr no</th><th>Particulars</th><th>Amount Rs in cr</th><th>%</th></tr>
<tr><td>1.</td><td>Revenue/Turnover</td><td>74.46 cr</td><td>32%</td></tr>
<tr><td>2.</td><td>Total Income</td><td>74.46 cr</td><td>32%</td></tr>
<tr><td>3.</td><td>Net worth</td><td>-</td><td>-</td></tr>
</table>
The Revenue / Total Income of listed Entity is 232.90cr.
</td></tr>
<tr><td>2</td><td>Date on which the agreement for sale has been entered into;</td><td>Not Applicable at this stage, as the proposal is presently at an exploratory stage and no definitive agreement for sale/disposal has been entered into by the Company.</td></tr>
<tr><td>3</td><td>The expected date of completion of sale/disposal;</td><td>The expected date of completion of the proposed sale/disposal is presently not ascertainable and shall depend upon the identification of a suitable prospective buyer, finalisation of commercial terms and receipt of requisite statutory, regulatory and shareholders' approvals, wherever applicable.</td></tr>
<tr><td>4</td><td>Consideration received/receivable from such sale/ disposal;</td><td>The consideration receivable, if any, has not yet been determined, as the proposal is at an exploratory stage and no valuation or definitive commercial terms have been finalized.</td></tr>
<tr><td>5</td><td>Brief details of buyer(s) and whether the buyers belongs to the promoter/promoter group/group companies. If yes, details thereof;</td><td>Not Applicable at this stage, as no prospective buyer has been identified or finalised by the Company. The requisite details shall be disclosed upon identification and finalisation of the prospective buyer, in accordance with applicable regulatory requirements.</td></tr>
</table>

6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	The applicability of related party transaction provisions shall be examined upon identification of the prospective buyer and finalisation of the proposed transaction. If the proposed transaction constitutes a Related Party Transaction, the same shall be undertaken subject to the requisite approvals and compliance with applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations, including the requirement of being on an arm's length basis, wherever applicable.
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	The proposed sale/disposal is presently being explored independently and is not contemplated as part of any Scheme of Arrangement. The applicability of Regulation 37A of the SEBI Listing Regulations and other applicable provisions shall be examined based on the final structure and terms of the proposed transaction. The Company shall obtain the requisite shareholders' approval and comply with all applicable regulatory requirements, including Regulation 37A, wherever applicable, before undertaking the proposed sale/disposal
8	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable at this stage, as the proposal is presently at an exploratory stage and no decision has been taken regarding the structure or mode of the proposed transaction, including whether the same would be undertaken by way of a slump sale.

***For* Mangalam Drugs and Organics Limited**

GOVARDHAN MURLIDHAR DHOOT

Digitally signed by GOVARDHAN MURLIDHAR DHOOT
Date: 2026.11.18 18:45:53 +05'30'

Govardhan Murlidhar Dhoot
Managing Director
DIN: 01240086